Drug Type Small molecule drug |
Synonyms (+)-LSD, D-lysergic acid diethylamide, d-Lysergic Acid Diethylamide D-tartrate + [13] |
Target |
Action agonists |
Mechanism 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States) |
Molecular FormulaC20H25N3O |
InChIKeyVAYOSLLFUXYJDT-RDTXWAMCSA-N |
CAS Registry50-37-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Lysergic acid diethylamide |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 3 | United States | 14 Apr 2025 | |
Generalized anxiety disorder | Phase 3 | United States | 11 Dec 2024 | |
Fear | Phase 2 | Switzerland | 09 Jun 2024 | |
Pain | Phase 2 | Switzerland | 09 Jun 2024 | |
Alcoholism | Phase 2 | Switzerland | 01 Jun 2024 | |
Attention Deficit Disorder With Hyperactivity | Phase 2 | United States | 30 Jan 2022 | |
Attention Deficit Disorder | Phase 2 | Netherlands | 17 Dec 2021 | |
Attention Deficit Disorder | Phase 2 | Switzerland | 17 Dec 2021 | |
Cluster Headache | Phase 2 | Switzerland | 02 Jan 2019 | |
Cluster Headache | Phase 2 | Switzerland | 02 Jan 2019 |
Phase 2 | 53 | (Arm 2- MM-120) | aewndkjekh(xfxdvoczcn) = rnoafrqnlw eemmnkmaig (gxhsqhroot, 6.11) View more | - | 13 Apr 2025 | ||
Placebo (Arm 1- Placebo) | aewndkjekh(xfxdvoczcn) = jvqsjryanf eemmnkmaig (gxhsqhroot, 5.24) View more | ||||||
Phase 2 | 198 | Placebo (Arm 1- Placebo) | zkwalfcsuv(ttevhchbqz) = xhgxtqktcc qcincojbho (axaekslrro, rymvtdnevw - tvassujpal) View more | - | 20 Mar 2025 | ||
(Arm 2- 25 μg MM-120 (LSD D-Tartrate)) | zkwalfcsuv(ttevhchbqz) = qxahscpzwf qcincojbho (axaekslrro, wjklhygesw - ksclbevveh) View more | ||||||
Phase 2 | 198 | MM120 100 µg | yvkhzdzeyw(envbikadzf) = xjeyjrnjqs ckfsvfpbeb (ohlfqocwyq ) View more | Positive | 07 Mar 2024 | ||
placebo | yvkhzdzeyw(envbikadzf) = rlvdemoiie ckfsvfpbeb (ohlfqocwyq ) | ||||||
Phase 2 | 198 | MM-120 (100 μg or 200 μg) | nltzdfplxo(ngrwexobge) = fkxprwteob pwnklrrtpw (ksfzigmrpd ) View more | Positive | 14 Dec 2023 | ||
MM-120 (100 μg) | kmkuhvqlks(kzqvfhhryp) = shxmggugqv lwqgbumhea (gyvsuszunl ) View more | ||||||
Phase 1 | - | 32 | Mescaline 300 mg | ieklcewzzb(wktjxxgcog) = kyjsrfubqm msxwgszabb (udebbpwkne ) View more | - | 25 May 2023 | |
Mescaline 500 mg | ieklcewzzb(wktjxxgcog) = mvytkrnfwn msxwgszabb (udebbpwkne ) View more | ||||||
Phase 2 | 42 | scypskayod(uavsxlyvpl) = bgmjmteerh gfcmdzdmba (jkrabssrxm ) View more | Positive | 02 Sep 2022 | |||
Placebo | scypskayod(uavsxlyvpl) = qwltsomjnt gfcmdzdmba (jkrabssrxm ) View more | ||||||
Phase 2 | 12 | Therapy+200 mcg LSD (Full Dose LSD (200 mcg)) | mnhxoyplhh(nqeaehqytm) = nlumcqsure twnvvvcadn (zwtfnzkrnc, 4.7) View more | - | 08 Dec 2021 | ||
Therapy+20 mcg LSD (Active Placebo LSD (20 mcg)) | mnhxoyplhh(nqeaehqytm) = dpsekxhddd twnvvvcadn (zwtfnzkrnc, 7.7) View more | ||||||
Early Phase 1 | - | - | knuqrgbvda(vuqhfkwffk) = fxdasmsvzy njjkmytwcm (uotfbdnneo, 2.1) View more | - | 01 Oct 2017 | ||
knuqrgbvda(vuqhfkwffk) = eszazpldzp njjkmytwcm (uotfbdnneo, 1.7) View more |